ATS View
KOENJA繁中

LabGenomics KRX:084650KOSDAQ

랩지노믹스 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked34since Sep 11

In Q3 2026, LabGenomics reported revenue of ₩13.7bn, down 40.7% year on year, and an operating loss of ₩3.5bn. LabGenomics (랩지노믹스) appeared in 0 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Nov 6 with 3 articles.

Filing signals Buyback 4 quarters of losses Delisting / halt risk Screener

LabGenomics quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩13.7bn-40.7%−₩3.5bn
margin −25.3%		−₩5.2bn
Q2 2026₩15.8bn-29.4%−₩6.9bn
margin −43.6%		−₩2.5bn
Q1 2026₩17.9bn-18.1%−₩4.2bn
margin −23.3%		−₩4.7bn
Q4 2025 derived₩20.9bn-5.3%−₩25.5bn
margin −122.0%		−₩40.9bn
Q3 2025₩23.0bn+6.4%−₩2.1bn
margin −9.2%		−₩3.5bn
Q2 2025₩22.3bn+0.3%−₩20.2bn
margin −90.4%		−₩14.7bn
Q1 2025₩21.9bn+10.1%−₩5.7bn
margin −26.1%		−₩5.4bn
Q4 2024 derived₩22.1bn+10.7%−₩5.6bn
margin −25.6%		−₩12.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

LabGenomics top stories 2 weeks, by number of outlets

  1. 1
    Labgenomics 16 trading days away from delisting crisis...1,000 won level key
    2 outlets · 3 articlesFirst report Nov 6 23:58 이데일리

Latest LabGenomics news Korean headlines